Longeveron (NASDAQ:LGVN – Get Free Report) and Valneva (NASDAQ:VALN – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.
Profitability
This table compares Longeveron and Valneva’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Longeveron | -1,977.59% | -223.19% | -150.20% |
| Valneva | -110.33% | -153.20% | -39.50% |
Earnings and Valuation
This table compares Longeveron and Valneva”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Longeveron | $1.20 million | 18.40 | -$22.70 million | ($9.90) | -0.70 |
| Valneva | $142.94 million | 4.43 | -$130.33 million | ($2.11) | -3.16 |
Longeveron has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
10.0% of Longeveron shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 7.4% of Longeveron shares are owned by insiders. Comparatively, 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
Longeveron has a beta of -0.25, suggesting that its stock price is 125% less volatile than the S&P 500. Comparatively, Valneva has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Longeveron and Valneva, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Longeveron | 1 | 1 | 1 | 0 | 2.00 |
| Valneva | 2 | 0 | 1 | 0 | 1.67 |
Longeveron presently has a consensus price target of $80.00, suggesting a potential upside of 1,056.07%. Valneva has a consensus price target of $9.30, suggesting a potential upside of 39.43%. Given Longeveron’s stronger consensus rating and higher probable upside, analysts clearly believe Longeveron is more favorable than Valneva.
Summary
Valneva beats Longeveron on 8 of the 13 factors compared between the two stocks.
About Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
About Valneva
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.
Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.
